Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellmid has signed an option to license agreement to supply its anti-midkine diagnostic antibodies for the validation on Fujikura Kasei's latex platform.
Subscribe to our email newsletter
According to the deal, Cellmid will receive initial fee besides additional payment if Fujikura decides on exercising its license option.
Upon any future sales of midkine diagnostic products by Fujikura, Cellmid will gain royalties.
Fujikura medical project division head Dr Hideyuki Kuroda said, "We are very excited about this opportunity as the midkine diagnostic platform lends itself to multiple, high value product development opportunities."
The agreement is expected to progress if Fujikura could reach limit of detection (LOD) of 500 picogram/mL midkine in serum on latex diagnostic platform.
Cellmid’s MK-ELISA detects midkine to an extent of 8 picogram/mL, and Fujikura is considering to reach a LOD near to that level using the same antibody pair on its latex platform.
Cellmid CEO Maria Halasz said, "Fujikura is the ideal partner for us as they have a strong focus on building their medical diagnostic business and consider midkine an important part of this commercial expansion."